A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.

Hui Liu,Wen Lei,Chaoting Zhang,Chunmei Yang,Juying Wei,QunYi Guo,Xiaojun Guo,Zhilu Chen,Ying Lu,Zheming Lu,Wenbin Qian

A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.

2019

Hui Liu
Wen Lei
Chaoting Zhang
Chunmei Yang
Juying Wei
QunYi Guo
Xiaojun Guo
Zhilu Chen
Ying Lu
Zheming Lu
Wenbin Qian

7557Background: The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has established efficacy in the treatment of refractory or relapsed (R/R) B-cell lymphoma. However, the existence of dif...

Keywords:

Refractory
Cancer research
Pathology
CD28
B-cell lymphoma
Lymphoma
Cell therapy
Chimeric antigen receptor
Receptor
Medicine
CD19

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations